<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01516086</url>
  </required_header>
  <id_info>
    <org_study_id>191-092</org_study_id>
    <nct_id>NCT01516086</nct_id>
  </id_info>
  <brief_title>A 12-Week Study in Adult Subjects With Asthma</brief_title>
  <official_title>A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects With Partly Controlled and Uncontrolled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dey</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-center, randomized, placebo controlled parallel-group study to Replicate&#xD;
      Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled&#xD;
      and Uncontrolled Asthma. Individual participation will be approximately 16 weeks, including&#xD;
      12 weeks of double-blind treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome measure is FEV1 (Forced Expiry Volume in 1 second) and the secondary&#xD;
      outcome measure is Peak Expiratory Flow Rate (PEFR), Asthma Control Questionnaire (ACQ),&#xD;
      Nighttime awakenings and rescue medication usage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 (Forced Expiry Volume in 1 second)</measure>
    <time_frame>FEV1 at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>PEFR at Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">498</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Fluticasone Propionate (FP) - arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP BID (twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone propionate (FP) - arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Propionate (FP) - arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLuticasone Propionate (FP) - Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Propionate (FP) - Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Arm 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo inhalation solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Propionate (FP)</intervention_name>
    <description>FP Inhalation BID</description>
    <arm_group_label>FLuticasone Propionate (FP) - Arm 4</arm_group_label>
    <arm_group_label>Fluticasone Propionate (FP) - Arm 5</arm_group_label>
    <arm_group_label>Fluticasone Propionate (FP) - arm 1</arm_group_label>
    <arm_group_label>Fluticasone Propionate (FP) - arm 3</arm_group_label>
    <arm_group_label>Fluticasone propionate (FP) - arm 2</arm_group_label>
    <arm_group_label>Placebo - Arm 6</arm_group_label>
    <other_name>No other names applicable</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A signed and dated written informed consent form prior to the conduct of any study&#xD;
             procedures&#xD;
&#xD;
          2. Males and females between ≥ 18 and ≤ 60 years old.&#xD;
&#xD;
          3. Non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more&#xD;
             than 10 pack-years (e.g., 1 pack [20 cigarettes] per day for 10 years).&#xD;
&#xD;
        6.Ability to understand and comply with the protocol requirements (including completion of&#xD;
        daily PEFR, PFT and ACQ), instructions and protocol-stated restrictions.&#xD;
&#xD;
        7.Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the&#xD;
        screening visit. WOCBP include: any female who has experienced menarche and is not&#xD;
        post-menopausal (defined as amenorrhea for at least 12 consecutive months), or has not&#xD;
        undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal&#xD;
        ligation). Women who are using acceptable contraceptive medications or devices to prevent&#xD;
        pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be&#xD;
        considered WOCBP.&#xD;
&#xD;
        WOCBP must agree to avoid becoming pregnant for the duration of the study by using adequate&#xD;
        contraception at study entry and throughout the trial. Examples of adequate contraception&#xD;
        include the following:&#xD;
&#xD;
          -  Norplant&#xD;
&#xD;
          -  Medroxyprogesterone acetate injection&#xD;
&#xD;
          -  Oral contraception&#xD;
&#xD;
          -  Double-barrier method (e.g., condom and spermicide)&#xD;
&#xD;
          -  Abstinence, with one of the above WOCBP will be advised to notify the Investigator of&#xD;
             any changes in their pregnancy status or any change in contraceptive use.&#xD;
&#xD;
             8.Agreement by subject to abide by the study protocol and its restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past or present disease, excluding asthma, which as judged by the investigator, may&#xD;
             place the subject at increased risk of complications, interfere with study&#xD;
             participation, or confound any of the study objectives These diseases include, but are&#xD;
             not limited to cardiovascular disease, malignancy, gastrointestinal disease, hepatic&#xD;
             disease, diabetes type I or uncontrolled diabetes, type II, renal disease,&#xD;
             haematological disease, neurological disease, endocrine disease or pulmonary disease&#xD;
             (including, but not confined to chronic bronchitis, emphysema, bronchiectasis, COPD,&#xD;
             eosinophilic bronchitis or pulmonary fibrosis).&#xD;
&#xD;
          2. An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to&#xD;
             Visit 2&#xD;
&#xD;
          3. A history of hypersensitivity to the study drug or its components, including albuterol&#xD;
             as rescue medication.&#xD;
&#xD;
          4. History of illegal drug or alcohol abuse within the past 5 years.&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Use of &gt; 8 inhalations per day of SABA on any two consecutive days from screening to&#xD;
             randomization (Visits 1 and 2).&#xD;
&#xD;
          7. Use of an investigational drug or device within 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imtiaz Chaudry</last_name>
    <role>Study Director</role>
    <affiliation>Dey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CU Pharmaceutical Research</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <disposition_first_submitted>November 24, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 24, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2014</disposition_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Controlled</keyword>
  <keyword>uncontrolled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

